Article
Hematology
Albain Chansavang, Aurelien Philippe, Ines Bozinovic, Khalil Ben Hadj Ali, David Smadja, Dominique Helley, Luc Darnige, Laetitia Mauge
Summary: This study evaluated the performance of a commercial ELISA method for detecting anti-FVIII IgG in patients with acquired hemophilia A. The results showed 100% sensitivity and specificity, and correlated with the traditional Bethesda assay. These data suggest the potential use of this method for both diagnosis and follow-up of AHA patients.
ANNALS OF HEMATOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Jeremy W. Jacobs, Savanah D. Gisriel, Krishna Iyer, Henry M. Rinder
Summary: Acquired hemophilia A, caused by autoantibodies against coagulation factor VIII, often presents as severe bleeding while lupus anticoagulants manifest clinically with increased thrombosis risk. The coexistence of acquired FVIII inhibitor and LA is rare, with this case highlighting the challenges in diagnosing prolonged PTT. Recognizing underlying hematologic disturbances in asymptomatic patients is crucial to prevent potential complications.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS
(2022)
Review
Hematology
Mikhail V. Ovanesov, Joseph W. Jackson, Basil Golding, Timothy K. Lee
Summary: This article discusses the factors to consider when choosing an assay for potency assignment and postadministration monitoring of new factor products, including the validity of the assay calibrated with the IS, the meaning of potency values in IU, standards of care for patients, clinical relevance between the assigned potency value and recovery value from clinical laboratories, and patient safety.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2021)
Article
Hematology
Wei Liu, Jiaying Liu, Feng Xue, Renchi Yang, Lei Zhang
Summary: The use of daratumumab to clear FVIII antibodies has shown promising results in treating refractory AHA, providing a new approach for managing this condition.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2023)
Article
Hematology
Lars L. F. G. Valke, Marieke J. A. Verhagen, Bart T. P. M. Mulders, Robert Polenewen, Nicole M. A. Blijlevens, Joop H. Jansen, Hassan Mansouritorghabeh, Einas Elsheikh, Birgit M. Reipert, Peter L. Turecek, James S. O'Donnell, Sanna R. Rijpma, Saskia E. M. Schols, Waander L. van Heerde, Danielle Meijer
Summary: The NusBA is a modified version of the NBA assay that can detect very low-titer inhibitors. It has added value in early inhibitor detection and therapy adjustments in patients with congenital HA and AHA.
THROMBOSIS RESEARCH
(2023)
Article
Immunology
Glaivy Batsuli, Jasmine Ito, Elizabeth S. York, Courtney Cox, Wallace Baldwin, Surinder Gill, Pete Lollar, Shannon L. Meeks
Summary: This study analyzed the internalization of FVIII complexed with epitope-mapped FVIII-specific IgG monoclonal antibodies by murine bone marrow-derived dendritic cells (BMDCs) in vitro, as well as the antibody development in hemophilia A (FVIII-/-) mice injected with FVIII-IC over time. The results showed that certain FVIII-IC subsets modulate the humoral response to FVIII in an epitope-dependent manner.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Hematology
Laura H. Bukkems, Tim Preijers, Max W. F. van Spengler, Frank W. G. Leebeek, Marjon H. Cnossen, Ron A. A. Mathot
Summary: This study used in silico simulations to analyze the pharmacokinetic differences of various extended half-life factor VIII concentrates, with BAY 94-9027 showing the largest increase in AUC and best target attainment compared to standard half-life factor VIII.
THROMBOSIS AND HAEMOSTASIS
(2021)
Article
Hematology
Joseph S. Gish, Lexi Jarvis, Kenneth C. Childers, Shaun C. Peters, Connor S. Garrels, Ian W. Smith, H. Trent Spencer, Christopher B. Doering, Pete Lollar, P. Clint Spiegel
Summary: The study reveals the structure of a therapeutically active fVIII construct complexed with an anti-C1 domain inhibitor, shedding light on the interaction between the antibody and fVIII, which may lead to the development of more effective and safe fVIII replacement therapies.
Article
Hematology
Masahiro Takeyama, Shoko Furukawa, Koji Yada, Kenichi Ogiwara, Naruto Shimonishi, Yuto Nakajima, Kuniyoshi Mizumachi, Mariko Noguchi-Sasaki, Midori Shima, Keiji Nogami
Summary: The study evaluated the ex vivo coagulant effects of emicizumab in PwAHAs during the clinical course, showing potential effectiveness in clinical situations for these patients.
THROMBOSIS AND HAEMOSTASIS
(2021)
Review
Medicine, General & Internal
Tracey Remmington, Sherie Smith
Summary: This study aimed to evaluate the efficacy and adverse effects of rituximab for acquired haemophilia A, but no trials meeting the selection criteria were found, therefore no conclusions could be drawn. It is suggested to continue monitoring and incorporating eligible trials in future research, while encouraging clinicians to base their treatment decisions on alternative, lower-quality sources of evidence.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2021)
Article
Hematology
Connie M. Arthur, Patricia E. Zerra, Sooncheon Shin, Jianmei Wang, Xeuzheng Song, Christopher B. Doering, Pete Lollar, Shannon Meeks, Sean R. Stowell
Summary: Recombinant factor VIII (FVIII) products are crucial for the treatment of hemophilia A, but the development of antibodies against FVIII can limit its effectiveness. This study shows that the source of the recombinant FVIII product can influence the development of antibodies, with BHK-derived products displaying greater immunogenicity. The higher levels of nonhuman carbohydrate alpha Gal on BHK-derived FVIII suggest that it may contribute to the formation of anti-FVIII antibodies.
Article
Hematology
Weiqing Jing, Christina K. Baumgartner, Feng Xue, Jocelyn A. Schroeder, Qizhen Shi
Summary: In this study, we found that pre-existing inhibitors can lead to the loss of platelet-FVIII expression, and this loss is mediated by cytotoxic CD8 T cells. This finding is crucial for the treatment of hemophilia A patients with inhibitors.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2023)
Article
Hematology
Anne-Fleur Zwagemaker, Fabienne R. Kloosterman, Samantha C. Gouw, Sara Boyce, Paul Brons, Marjon H. Cnossen, Peter W. Collins, Jeroen Eikenboom, Charles Hay, Rutger C. C. Hengeveld, Shannon Jackson, Caroline A. M. Klopper-Tol, Marieke J. H. A. Kruip, Britta Laros-van Gorkom, Christoph Male, Laurens Nieuwenhuizen, Susan Shapiro, Karin Fijnvandraat, Michiel Copens
Summary: This study investigated the discrepancy between one-stage and chromogenic assays of coagulation factor activity in moderate and mild hemophilia A and B patients. The results showed that only a small number of patients exhibited a discrepancy between the two assays, and this discrepancy was largely determined by laboratory variables.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2023)
Article
Hematology
Nasim Shahidi Hamedani, Anouk Anna Marie Therese Donners, Matthijs van Luin, Simone Gasper, Heiko Ruehl, Claudia Klein, Thilo Albert, Mohsin EL Amrani, Bernd Poetzsch, Johannes Oldenburg, Jens Mueller
Summary: This study evaluated the impact of plasma FVIII activity on determining emicizumab levels and proposed different strategies for correcting or preanalytical inhibition of FVIII. The results showed that inhibitor-based FVIII neutralization is a feasible strategy for accurately measuring plasma emicizumab levels in the presence of FVIII activity.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2023)
Article
Biochemistry & Molecular Biology
Marcela Montilla, Isabel Atienza-Navarro, Francisco Jose Garcia-Cozar, Carmen Castro, Francisco Javier Rodriguez-Martorell, Felix A. Ruiz
Summary: Polyphosphate (polyP) plays an important modulatory role in the binding of von Willebrand factor (VWF) and Factor VIII (FVIII) in blood coagulation, and may be used in developing new therapies to activate VWF.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Editorial Material
Immunology
Varun Kumar Sharma, Jagadeesh Bayry
CELLULAR & MOLECULAR IMMUNOLOGY
(2022)
Article
Immunology
Srinivasa Reddy Bonam, Camille Chauvin, Laurine Levillayer, Mano Joseph Mathew, Anavaj Sakuntabhai, Jagadeesh Bayry
Summary: This study reports that SARS-CoV-2 induces cytokine responses, particularly IL-13, in both resting and IL-3 primed basophils. However, the expression of surface markers associated with basophil activation and PD-L1 expression on basophils are not affected by SARS-CoV-2. The results suggest that basophil cytokine responses to SARS-CoV-2 might help reduce inflammation and promote antibody responses to the virus.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Nabarun Chandra Das, Pritha Chakraborty, Jagadeesh Bayry, Suprabhat Mukherjee
Summary: In this study, the binding abilities of eight monoclonal antibodies (mAbs) against Alpha and Delta variants of SARS-CoV-2 were assessed using computational modeling. Several mAbs were found to effectively neutralize these variants. Based on these findings, a chimeric antibody was designed to combat potential antibody-mediated neutralization escape.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Srinivasa Reddy Bonam, Peter Paul Platenburg, Jagadeesh Bayry
Summary: In this study, the immunopotentiating mechanism of an oil-in-water emulsion-based vaccine adjuvant called LiteVax Adjuvant (LVA) was analyzed. The researchers investigated the effect of LVA and its components on the function of dendritic cells (DC), which play a crucial role in the immune response. They found that the component CMS significantly enhanced DC activation markers, cytokine secretion, and CD4(+) T cell responses. This study identified the unique role of CMS in LVA and proposed that LVA acts as a delivery system while CMS acts as an immunostimulatory agent.
FRONTIERS IN IMMUNOLOGY
(2023)
Editorial Material
Rheumatology
Chetan Sharma, Jagadeesh Bayry
Summary: The full understanding of post-COVID-19 autoimmune diseases and their prevalence is limited. However, two large-scale studies have found a significant increase in the risk of developing various new-onset autoimmune diseases linked to SARS-CoV-2 infection.
NATURE REVIEWS RHEUMATOLOGY
(2023)
Review
Pharmacology & Pharmacy
Sruthi Vijaya Retnakumar, Camille Chauvin, Jagadeesh Bayry
Summary: T cell exhaustion is a major obstacle in mounting immune responses against chronic infections and cancers. Immune checkpoint (ICP) molecules, especially PD-1, contribute to T cell dysfunction. Blocking PD-1 can reverse T cell exhaustion and stimulate the impaired immune system. The interaction between vaccine responses and ICP therapy needs further exploration.
PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Immunology
Carole El Hachem, Pierre Marschall, Pierre Hener, Anupama Karnam, Srinivasa Reddy Bonam, Pierre Meyer, Eric Flatter, Marie-Christine Birling, Jagadeesh Bayry, Mei Li
Summary: This study investigates the mechanisms of basophil recruitment to allergic skin using a mouse model of allergic contact dermatitis. It demonstrates that IL-3 produced by T cells mediates the extravasation of basophils by activating the expression of ALDH1A2, which is responsible for the production of retinoic acid. IL-3 also induces the expression of integrins involved in basophil extravasation.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Allergy
Jagadeesh Bayry, Eisha A. Ahmed, Diana Toscano-Rivero, Nicholas Vonniessen, Genevieve Genest, Casey G. Cohen, Marieme Dembele, Srini Kaveri, Bruce D. Mazer
Summary: Intravenous immunoglobulin (IVIG) plays a crucial role in the treatment of humoral immune deficiencies and inflammatory disorders. While targeted therapies are emerging, the multifunctionality of IVIG as both an effector and regulatory molecule is noteworthy. This article explores the mechanism of action of IVIG in various resistant conditions and highlights mechanistic studies that shed light on its effects on both innate and adaptive immune responses.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2023)
Editorial Material
Immunology
Sruthi Vijaya Retnakumar, Srinivasa Reddy Bonam, Haitao Hu, Jagadeesh Bayry
Article
Biology
Cyril Planchais, Remi Noe, Marie Gilbert, Maxime Lecerf, Srini V. Kaveri, Sebastien Lacroix-Desmazes, Lubka T. Roumenina, Jordan D. Dimitrov
Summary: Intravascular hemolysis occurs in various pathological conditions, and extracellular hemoglobin and heme play a role in the pathogenesis of hemolytic diseases. This study demonstrates that oxidized hemoglobin can modify the binding characteristics of human immunoglobulins, leading to the binding of unrelated self-proteins. The transfer of heme from methemoglobin to IgG is essential for this acquisition of antibody polyreactivity.
COMMUNICATIONS BIOLOGY
(2023)
Article
Immunology
Nabarun Chandra Das, Pritha Chakraborty, Jagadeesh Bayry, Suprabhat Mukherjee
Summary: Mutation(s) in the spike protein is a major characteristic trait of newly emerged SARS-CoV-2 variants. Omicron, the latest variant, is highly transmissible and can escape host immunity. The study found that adintivimab, beludivimab, and regadanivimab are the most potent monoclonal antibodies in neutralizing Omicron variants.
Article
Multidisciplinary Sciences
Cyril Planchais, Luis M. Molinos-Albert, Pierre Rosenbaum, Thierry Hieu, Alexia Kanyavuz, Dominique Clermont, Thierry Prazuck, Laurent Lefrou, Jordan D. Dimitrov, Sophie Hue, Laurent Hocqueloux, Hugo Mouquet
Summary: The timing of antiretroviral therapy affects the repertoire of intestinal memory B cells and plasmablasts in HIV-1-infected individuals. Early treatment reduces the abnormal expression of class-switched memory B cells, while late-treated individuals show increased polyreactivity to commensal bacteria in both intestinal B cells and serum IgA. These abnormalities correlate with intestinal permeability and systemic inflammation markers.
NATURE COMMUNICATIONS
(2023)
Editorial Material
Cell Biology
Camille Chauvin, Sruthi Vijaya Retnakumar, Jagadeesh Bayry
Summary: Severe obesity speeds up the decline of neutralizing antibodies to COVID-19 vaccines, increasing the risk of hospitalization from breakthrough SARS-CoV-2 infections. These findings have implications for vaccination policies for SARS-CoV-2 variants and other infectious diseases like influenza in the obese population.
CELL REPORTS MEDICINE
(2023)
Article
Multidisciplinary Sciences
Camille Chauvin, Laurine Levillayer, Mathilde Roumier, Hubert Nielly, Claude Roth, Anupama Karnam, Srinivasa Reddy Bonam, Anne Bourgarit, Clement Dubost, Aurore Bousquet, Sebastien Le Burel, Raphaele Mestiri, Daminen Sene, Joris Galland, Marc Vasse, Matthieu Groh, Mathilde Le Marchand, Camille Vassord-Dang, Jean-Francois Gautier, Pham-Thi Nhan, Christian Verny, Bruno Pitaro, Cyril Planchais, Hugo Mouquet, Richard Paul, Etienne Simon-Loriere, Jagadeesh Bayry, Laurent Gilardin, Anavaj Sakuntabhai
Summary: Although tocilizumab treatment has shown efficacy in severe COVID-19 patients, its short-term use does not affect B cell sub-populations and cross-neutralization of SARS-CoV-2 variants in convalescent COVID-19 patients. The study found that SARS-CoV-2-specific IgG1 titers were dependent on disease severity rather than tocilizumab treatment. Both treated and non-treated patients had strong neutralizing activity against ancestral and several variants of SARS-CoV-2, but weaker activity against the Gamma and Omicron variants. Overall, tocilizumab therapy did not modify the robustness of cell and IgG responses to Spike antigens.
Meeting Abstract
Biophysics
Borja Rodriguez de Francisco, Isabel Valsecchi, Ariane Pille, Chi L. Pham, Vincent Dupres, Frank Lafont, Jagadesh Bayry, Vishukumar Aimanianda, Margaret Sunde, Inaki Guijarro
BIOPHYSICAL JOURNAL
(2022)